APA (7th ed.) Citation

BA, D., A, M., J, C., K, J., A, R., T, K., . . . AJ, J. (2024). Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood cancer journal, 14(1), 170. https://doi.org/10.1038/s41408-024-01156-x

Chicago Style (17th ed.) Citation

BA, Derman, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, and Jakubowiak AJ. "Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)." Blood Cancer Journal 14, no. 1 (2024): 170. https://doi.org/10.1038/s41408-024-01156-x.

MLA (9th ed.) Citation

BA, Derman, et al. "Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)." Blood Cancer Journal, vol. 14, no. 1, 2024, p. 170, https://doi.org/10.1038/s41408-024-01156-x.